NCT04971005View on ClinicalTrials.gov

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

February 4, 2022

Study Completion Date

February 4, 2022

Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
DRUG

Autologous Hematopoietic Stem Cell Transplantation

Autologous Hematopoietic Stem Cell Transplantation

DRUG

Ocrelizumab

600 mg every 6 months continuously

DRUG

Alemtuzumab

12 mg/day for 5 consecutive days and again after 365 days for 3 days

Trial Locations (2)

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

68167

Universitätsklinikum Mannheim, Mannheim

Sponsors
All Listed Sponsors
collaborator

Neovii Biotech

INDUSTRY

collaborator

Clinical Trial Center North (CTC North GmbH & Co. KG)

OTHER

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT04971005 - Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial | Biotech Hunter | Biotech Hunter